vs
Cherry Hill Mortgage Investment Corp（CHMI）与STANDARD BIOTOOLS INC.（LAB）财务数据对比。点击上方公司名可切换其他公司
STANDARD BIOTOOLS INC.的季度营收约是Cherry Hill Mortgage Investment Corp的1.7倍（$19.6M vs $11.8M），STANDARD BIOTOOLS INC.同比增速更快（-11.5% vs -37.2%），过去两年STANDARD BIOTOOLS INC.的营收复合增速更高（-12.2% vs -15.2%）
Cherry Hill Mortgage Investment Corp是一家总部位于美国的房地产金融企业，核心业务为收购、投资及管理住宅抵押贷款相关资产，包括机构抵押贷款支持证券、住宅抵押贷款及抵押贷款服务权，主要面向美国本土住房金融市场运营。
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
CHMI vs LAB — 直观对比
营收规模更大
LAB
是对方的1.7倍
$11.8M
营收增速更快
LAB
高出25.7%
-37.2%
两年增速更快
LAB
近两年复合增速
-15.2%
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $11.8M | $19.6M |
| 净利润 | — | $-34.7M |
| 毛利率 | 78.9% | 48.5% |
| 营业利润率 | 72.1% | -168.5% |
| 净利率 | — | -177.4% |
| 营收同比 | -37.2% | -11.5% |
| 净利润同比 | — | -28.8% |
| 每股收益（稀释后） | $0.18 | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CHMILAB
| Q4 25 | $11.8M | — | ||
| Q3 25 | $8.6M | $19.6M | ||
| Q2 25 | $6.0M | $21.8M | ||
| Q1 25 | $-3.0M | $40.8M | ||
| Q4 24 | $18.7M | — | ||
| Q3 24 | $-7.1M | $22.1M | ||
| Q2 24 | $6.6M | $22.5M | ||
| Q1 24 | $16.3M | $45.5M |
净利润CHMILAB
| Q4 25 | — | — | ||
| Q3 25 | $4.5M | $-34.7M | ||
| Q2 25 | $1.6M | $-33.5M | ||
| Q1 25 | $-7.0M | $-26.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-12.4M | $-26.9M | ||
| Q2 24 | $784.0K | $-45.7M | ||
| Q1 24 | $12.1M | $-32.2M |
毛利率CHMILAB
| Q4 25 | 78.9% | — | ||
| Q3 25 | 73.2% | 48.5% | ||
| Q2 25 | 67.7% | 48.8% | ||
| Q1 25 | 183.4% | 48.4% | ||
| Q4 24 | 83.3% | — | ||
| Q3 24 | 145.3% | 54.9% | ||
| Q2 24 | 47.5% | 46.1% | ||
| Q1 24 | 83.9% | 53.1% |
营业利润率CHMILAB
| Q4 25 | 72.1% | — | ||
| Q3 25 | 56.0% | -168.5% | ||
| Q2 25 | 44.4% | -118.1% | ||
| Q1 25 | 223.6% | -80.8% | ||
| Q4 24 | 76.2% | — | ||
| Q3 24 | 171.8% | -120.9% | ||
| Q2 24 | 22.0% | -134.5% | ||
| Q1 24 | 78.0% | -132.2% |
净利率CHMILAB
| Q4 25 | — | — | ||
| Q3 25 | 52.7% | -177.4% | ||
| Q2 25 | 25.9% | -153.7% | ||
| Q1 25 | 229.2% | -63.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | 175.8% | -122.0% | ||
| Q2 24 | 11.9% | -203.3% | ||
| Q1 24 | 73.7% | -70.6% |
每股收益（稀释后）CHMILAB
| Q4 25 | $0.18 | — | ||
| Q3 25 | $0.05 | $-0.09 | ||
| Q2 25 | $-0.03 | $-0.09 | ||
| Q1 25 | $-0.29 | $-0.07 | ||
| Q4 24 | $0.30 | — | ||
| Q3 24 | $-0.49 | $-0.07 | ||
| Q2 24 | $-0.06 | $-0.12 | ||
| Q1 24 | $0.32 | $-0.27 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $54.9M | $129.4M |
| 总债务越低越好 | $146.3M | — |
| 股东权益账面价值 | $236.0M | $399.7M |
| 总资产 | $1.5B | $539.6M |
| 负债/权益比越低杠杆越低 | 0.62× | — |
8季度趋势，按日历期对齐
现金及短期投资CHMILAB
| Q4 25 | $54.9M | — | ||
| Q3 25 | $55.4M | $129.4M | ||
| Q2 25 | $58.0M | $158.6M | ||
| Q1 25 | $47.3M | $150.9M | ||
| Q4 24 | $46.3M | — | ||
| Q3 24 | $50.2M | $210.6M | ||
| Q2 24 | $52.4M | $269.8M | ||
| Q1 24 | $47.5M | $287.1M |
总债务CHMILAB
| Q4 25 | $146.3M | — | ||
| Q3 25 | $148.0M | — | ||
| Q2 25 | $150.1M | — | ||
| Q1 25 | $150.1M | — | ||
| Q4 24 | $152.1M | — | ||
| Q3 24 | $151.8M | $55.2M | ||
| Q2 24 | $160.5M | $55.1M | ||
| Q1 24 | $167.5M | $55.0M |
股东权益CHMILAB
| Q4 25 | $236.0M | — | ||
| Q3 25 | $233.1M | $399.7M | ||
| Q2 25 | $229.9M | $424.5M | ||
| Q1 25 | $226.6M | $454.6M | ||
| Q4 24 | $230.3M | — | ||
| Q3 24 | $236.7M | $489.3M | ||
| Q2 24 | $234.5M | $510.3M | ||
| Q1 24 | $247.0M | $577.3M |
总资产CHMILAB
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.5B | $539.6M | ||
| Q2 25 | $1.5B | $557.0M | ||
| Q1 25 | $1.4B | $579.6M | ||
| Q4 24 | $1.5B | — | ||
| Q3 24 | $1.6B | $681.5M | ||
| Q2 24 | $1.4B | $708.7M | ||
| Q1 24 | $1.4B | $777.7M |
负债/权益比CHMILAB
| Q4 25 | 0.62× | — | ||
| Q3 25 | 0.63× | — | ||
| Q2 25 | 0.65× | — | ||
| Q1 25 | 0.66× | — | ||
| Q4 24 | 0.66× | — | ||
| Q3 24 | 0.64× | 0.11× | ||
| Q2 24 | 0.68× | 0.11× | ||
| Q1 24 | 0.68× | 0.10× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $19.1M | $-22.2M |
| 自由现金流经营现金流 - 资本支出 | — | $-23.1M |
| 自由现金流率自由现金流/营收 | — | -118.1% |
| 资本支出强度资本支出/营收 | — | 4.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-111.1M |
8季度趋势，按日历期对齐
经营现金流CHMILAB
| Q4 25 | $19.1M | — | ||
| Q3 25 | $-2.4M | $-22.2M | ||
| Q2 25 | $12.5M | $-20.7M | ||
| Q1 25 | $682.0K | $-30.3M | ||
| Q4 24 | $-4.7M | — | ||
| Q3 24 | $4.4M | $-27.9M | ||
| Q2 24 | $4.1M | $-39.0M | ||
| Q1 24 | $-19.1M | $-62.5M |
自由现金流CHMILAB
| Q4 25 | — | — | ||
| Q3 25 | — | $-23.1M | ||
| Q2 25 | — | $-22.6M | ||
| Q1 25 | — | $-35.3M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-30.1M | ||
| Q2 24 | — | $-41.0M | ||
| Q1 24 | — | $-63.3M |
自由现金流率CHMILAB
| Q4 25 | — | — | ||
| Q3 25 | — | -118.1% | ||
| Q2 25 | — | -103.6% | ||
| Q1 25 | — | -86.6% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -136.4% | ||
| Q2 24 | — | -182.2% | ||
| Q1 24 | — | -138.9% |
资本支出强度CHMILAB
| Q4 25 | — | — | ||
| Q3 25 | — | 4.5% | ||
| Q2 25 | — | 8.7% | ||
| Q1 25 | — | 12.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 10.2% | ||
| Q2 24 | — | 8.6% | ||
| Q1 24 | — | 1.7% |
现金转化率CHMILAB
| Q4 25 | — | — | ||
| Q3 25 | -0.53× | — | ||
| Q2 25 | 7.98× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 5.18× | — | ||
| Q1 24 | -1.58× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CHMI
暂无分部数据
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
